This a valuable step forward in stakeholder communications – integrating Sanofi’s strategic, financial, scientific and ESG achievements and ambitions. We are very proud to have contributed to this important project.

“I’ve been at Sanofi for close to five years and continue to be impressed with what all of the teams accomplished in a relatively short period of time. A great deal of positive change across the company and for the people and communities we serve!
At the end of 2022 we closed the first chapter of our ‘Play to Win’ strategy successfully with 10 consecutive quarters of growth. Achieving our target 30% BOI margin, while our reinvestment strategy in R&D has translated into breakthrough science and transformative medicines. We’ve also doubled down on our commitment to society, with a sharpened focus on creating a more equitable and sustainable world.
Moving into the next chapter of ‘Play to Win’, we are approaching the steady state of transformative launches, breakthrough science and CSR progress. There is still a lot of work to do, but our commitment to improving people’s lives across the world will push us forward.”

Read more in our 2022 Annual Shareholder Report: